HLB Pharmaceutical Co. Ltd (047920) - Total Assets
Based on the latest financial reports, HLB Pharmaceutical Co. Ltd (047920) holds total assets worth ₩167.93 Billion KRW (≈ $113.80 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 047920 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
HLB Pharmaceutical Co. Ltd - Total Assets Trend (2014–2024)
This chart illustrates how HLB Pharmaceutical Co. Ltd's total assets have evolved over time, based on quarterly financial data. Explore HLB Pharmaceutical Co. Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
HLB Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
HLB Pharmaceutical Co. Ltd's total assets of ₩167.93 Billion consist of 40.1% current assets and 59.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩10.49 Billion | 6.6% |
| Accounts Receivable | ₩16.10 Billion | 10.2% |
| Inventory | ₩22.86 Billion | 14.5% |
| Property, Plant & Equipment | ₩34.02 Billion | 21.5% |
| Intangible Assets | ₩4.84 Billion | 3.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how HLB Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see HLB Pharmaceutical Co. Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HLB Pharmaceutical Co. Ltd's current assets represent 40.1% of total assets in 2024, a decrease from 62.3% in 2014.
- Cash Position: Cash and equivalents constituted 6.6% of total assets in 2024, down from 8.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 2.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 21.5% of total assets.
HLB Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of HLB Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
HLB Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.95 | 2.33 | 1.53 |
| Quick Ratio | 1.25 | 1.71 | 1.42 |
| Cash Ratio | 0.00 | 0.43 | 0.00 |
| Working Capital | ₩40.46 Billion | ₩46.50 Billion | ₩33.00 Billion |
HLB Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between HLB Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.39 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 11.7% |
| Total Assets | ₩157.93 Billion |
| Market Capitalization | $267.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values HLB Pharmaceutical Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: HLB Pharmaceutical Co. Ltd's assets grew by 11.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for HLB Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual total assets of HLB Pharmaceutical Co. Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩157.93 Billion ≈ $107.03 Million |
+11.73% |
| 2023-12-31 | ₩141.35 Billion ≈ $95.79 Million |
-0.58% |
| 2022-12-31 | ₩142.18 Billion ≈ $96.35 Million |
+11.40% |
| 2021-12-31 | ₩127.63 Billion ≈ $86.49 Million |
+14.55% |
| 2020-12-31 | ₩111.42 Billion ≈ $75.51 Million |
+140.16% |
| 2019-12-31 | ₩46.39 Billion ≈ $31.44 Million |
+27.38% |
| 2018-12-31 | ₩36.42 Billion ≈ $24.68 Million |
-8.59% |
| 2017-12-31 | ₩39.85 Billion ≈ $27.00 Million |
-3.37% |
| 2016-12-31 | ₩41.24 Billion ≈ $27.95 Million |
+65.96% |
| 2015-12-31 | ₩24.85 Billion ≈ $16.84 Million |
+15.92% |
| 2014-12-31 | ₩21.43 Billion ≈ $14.53 Million |
-- |
About HLB Pharmaceutical Co. Ltd
HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, anti… Read more